Action 002603 SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Actions

002603

CNE1000015S0

Cours en clôture Shenzhen S.E.
Autres places de cotation
 00:00:00 24/04/2024 		Varia. 5j. Varia. 1 janv.
19,28 CNY -0,46 % Graphique intraday de Shijiazhuang Yiling Pharmaceutical Co., Ltd. +0,57 % -16,43 %
2023 Yiling Pharmaceutical obtient le feu vert pour des essais cliniques en Chine sur un médicament contre la trachéobronchite MT
2023 Les comprimés Lianhua Qingke de Yiling Pharmaceutical obtiennent l'autorisation de devenir un médicament en vente libre ; les actions augmentent de 4%. MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Yiling Pharmaceutical Gets Nod for China Clinical Trial of Tracheobronchitis Drug
Yiling Pharmaceutical's Lianhua Qingke Tablets Gets Nod to Become Over-the-Counter Drug; Shares Up 4%
Yiling Pharmaceutical Gets Nod to Trial Huoxia Cold Granules
Yiling Pharmaceutical Presents Clinical Data on Cardiovascular Drug at Beijing Conference
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Yiling Pharmaceutical Gets Green Light to Trial Acute Myeloid Leukemia Drug
Yiling Pharmaceutical Gets Greenlight to Trial G201-Na Capsules
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Announces Implementation of Cash Dividend for 2022, Payable on 17 July 2023
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Approves Cash Dividend for 2022
Yiling Pharma's Hypertension Drug Passes Regulatory Evaluation in China
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for 2022
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Yiling Pharma Wins Nod to Trial Prostate Cancer Drug
Yiling Pharma Unit Gets Marketing Rights of Rujietai Capsules
Shijiazhuang Yiling Pharma Appoints Founder as Honorary Chairman
Yiling Pharma Gets Regulatory Nod for Traditional Chinese Medicine
Yiling Pharma’s Antibiotic Passes Consistency Test
Shijiazhuang Yiling’s Depression Drug Included in China’s Medical Insurance Catalog
Yiling Pharma’s Traditional Chinese Medicine Added to Government's Recommended Drugs For COVID-19
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 002603
  4. Actualités Shijiazhuang Yiling Pharmaceutical Co., Ltd.
  5. Autres langues